Ceramide NanoLiposome in Patients with Advanced Solid Tumors

Study Name
Ceramide NanoLiposome in Patients with Advanced Solid Tumors
ClinicalTrials.gov Identifier (if applicable)
NCT02834611
Study Center
Institution Name
University of Maryland, Greenebaum Cancer Center
Institution Address
22 South Greene Street
City
Baltimore
State
Maryland
Zip Code
21201
Phone
(800) 492-5538
Website
http://www.umm.edu/programs/cancer
List additional Institutions (include address, phone number, and website)
Medical University of South Carolina, Hollings Cancer Center
86 Jonathan Lucas Street
Charleston, SC 29425
843-792-9300
http://www.hollingscancercenter.org/index.htmlUniversity of Virginia, Emily Couric Clinical Cancer Center
1240 Lee Street
Charlottesville, VA 22903
434-924-9333
https://uvahealth.com/locations/profile/emily-couric-clinical-cancer-center
Study Contacts
Principal Investigator
Edward Sausville, MD, PhD
P.I. Phone
(800) 492-5538
P.I. Email
cheryl.young@umm.edu
List additional Principal Investigators (include phone number and email)
Carolyn Britten, MD, Medical University of South Carolina
britten@musc.eduRobert Dreicer, MD, UVA Cancer Center
rd7va@hscmail.mcc.virginia.edu
434-982-4798
Study Coordinator
Cheryl Young, University of Maryland
Study Coordinator Phone
(410) 328-8611
Study Coordinator Email
cheryl.young@umm.edu
List additional Study Coordinators (include phone number and email)
Alan Brisendine, Medical University of South Carolina
843-792-9007
brisend@musc.eduSue Jones, University of Virginia
434-924-9199
syt8a@virginia.edu
OVERVIEW – in layman’s terms (150 words max)
This study is a dose escalation study to determine the safety and tolerability of Ceramide NanoLiposome in patients with advanced solid tumors.
Enrollment
18-48
Study Start Date
03/28/2017
Estimated Completion Date
09/28/2018
Translate »

Pin It on Pinterest